Company Description
YD Bio Limited, a biopharmaceutical company, focuses on regulated diagnostics, life science clinical services, and healthcare product commercialization in the United States and Taiwan.
The company offers eye disease treatment products, 3D LensMate Artificial Tears, a natural tear-mimicking lubricant that moisturizes the eyes and relieves dry eye symptoms; 3D LensMate Eye Drops, an ophthalmic solution to alleviate symptoms of dry eye syndrome, including irritation, foreign body sensation, and eye fatigue; and LSC Eye Drug/Injection, an injectable ophthalmic drug is being developed for the treatment of various retinal and macular disorders, such as age-related macular degeneration, macular edema, choroidal and subretinal neovascularization, and neovascular glaucoma.
It also provides Hydrogel (Hioxifilcon A) Soft (Hydrophilic) Contact Lens, a spherical and aspherical lenses.
In addition, the company supplies drugs and medical materials for clinical trials; and operates DNA methylation-based oncology testing programs.
Further, it provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination, and compliance-focused support for clinical development programs to pharmaceutical and biotechnology companies.
It serves corporate and retail customers. The company was founded in 2013 and is based in Taipei, Taiwan.
| Country | Taiwan |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Ethan Shen |
Contact Details
Address: No. 3, Xingnan St., 12F. Taipei, 115001 Taiwan | |
| Phone | 886 2382 0330 |
| Website | ydesgroup.com |
Stock Details
| Ticker Symbol | YDES |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 2011674 |
| CUSIP Number | G98301107 |
| ISIN Number | KYG983011076 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ethan Shen Ph.D. | Chief Executive Officer and Chairman |
| Edmund Hen CPA, F.C.A., M.S. | Chief Financial Officer |
| Dr. Benjamin Zhang M.D. | Chief Medical Officer and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 1, 2026 | 424B3 | Prospectus |
| Sep 1, 2026 | 6-K | Report of foreign issuer |
| Aug 11, 2026 | 424B3 | Prospectus |
| Aug 11, 2026 | 6-K | Report of foreign issuer |
| May 29, 2026 | EFFECT | Notice of Effectiveness |
| May 26, 2026 | POS AM | Post-Effective amendments for registration statement |
| May 1, 2026 | 6-K | Report of foreign issuer |
| Apr 30, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Feb 27, 2026 | 424B3 | Prospectus |
| Feb 26, 2026 | 6-K | Report of foreign issuer |